HomeFile

File

View Category
Antithrombotic Anticoagulants

Are Antithrombotics Necessary in Outpatients after COVID-19?

According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits...
solaci -
Learn More
Other

Hypertensive Patients: Maximizing Doses or Adding New Drugs

Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes...
solaci -
Learn More
Coronary disease

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat...
solaci -
Learn More
Institutional News

SOLACI-CACI 2021 Webinar | Challenges in TAVI – Severe CAD & Coronary Occlusion

Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company...
solaci -
Learn More
Structural heart disease

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this...
solaci -
Learn More
Acute coronary syndromes

STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients

One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety...
solaci -
Learn More
Structural heart disease

The FDA Approves a Third Device in the TAVR Race

The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three...
solaci -
Learn More
Institutional News

The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not...
solaci -
Learn More